The three drugs are J&J’s Remicade, Bristol Myers Squibb’s Orencia and AbbVie’s investigational drug CVC. They’re all used to control immune systems.
The trial will see whether the drugs can treat respiratory distress and organ failure in severely ill COVID-19 patients, according to the Journal. It’s expected to last up to 8 months and will enroll about 2,100 patients.
All patients also will receive remdesivir. The trial will evaluate whether the drugs lower severity of the disease, recovery time, death rate and use of hospital resources.
Read the full article here.
More articles on pharmacy:
CVS to hire 15,000 employees for flu season
Walgreens, CVS will offer free COVID-19 vaccines at long-term care facilities
FDA grants first-ever Ebola drug approval to Regeneron
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
